US-based Massive Bio and QC Healthcare have entered a partnership to improve access for cancer patients to clinical trials, coordinated care, and telehealth services.
The companies have formalised their collaboration with a memorandum of understanding (MoU).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This collaboration seeks to address barriers that prevent many adult cancer patients from enrolling in clinical trials.
It will provide on-demand telehealth access to licensed providers for trial participants, reducing emergency department visits, and improving patient retention and adherence within clinical trials.
Massive Bio and QC Healthcare also intend to use outreach that complies with regulatory standards to inform eligible patients about trial opportunities.
The approach is designed to support patients throughout their treatment journey, from initial trial awareness and navigation through to acute care and long-term coordination, while collecting data to inform the development of future cancer therapies.
Massive Bio co-founder and CEO Selin Kurnaz said: “Matching a patient to the right clinical trial is only the beginning. Cancer patients need continuous, coordinated support to stay on their treatment journey, and that has long been the missing piece.
“By combining our AI-driven matching and navigation with QC Healthcare’s nationwide care delivery, we’re building an access model that meets patients where they are, keeps them in trials longer, and produces the evidence that moves oncology forward.”
The partnership will proceed in phases, initially focusing on support services and coordination for trial participants.
Later stages are expected to further integrate oncology telehealth consultations and survivorship support as QC Healthcare launches its platform, My Oncology Doctor.
Both companies plan to consider additional joint technology and data initiatives in the future.
In May 2026, Massive Bio signed a strategic partnership with Just Worldwide to connect more cancer patients to clinical studies.
